Common Contracts
28 similar Underwriting Agreement contracts by Acceleron Pharma Inc, Loxo Oncology, Inc., TESARO, Inc., others
Blackstone Mortgage Trust, Inc. [ ] Shares 1 Class A Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • July 29th, 2022 • Blackstone Mortgage Trust, Inc. • Real estate investment trusts • New York
Blackstone Mortgage Trust, Inc., a corporation organized under the laws of the State of Maryland (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of class A common stock, par value $0.01 per share (the “Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Under
GENENTA SCIENCE S.P.A. 1,608,695 American Depositary Shares Representing 1,608,695 Ordinary Shares (no par value) Underwriting AgreementUnderwriting Agreement • November 24th, 2021 • Genenta Science S.p.A. • Biological products, (no disgnostic substances) • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
GENENTA SCIENCE S.P.A. [●] American Depositary Shares Representing [●] Ordinary Shares ([●] par value) Underwriting AgreementUnderwriting Agreement • November 9th, 2021 • Genenta Science S.p.A. • Biological products, (no disgnostic substances) • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
Acceleron Pharma Inc. 4,864,864 Shares1 Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • July 2nd, 2020 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
Acceleron Pharma Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 4,864,864 shares of common stock, $0.001 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 729,729 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used he
Acceleron Pharma Inc. 5,348,838 Shares(1) Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • January 17th, 2019 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
Acceleron Pharma Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,348,838 shares of common stock, $0.001 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 802,325 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used he
Acceleron Pharma Inc. 5,405,406 Shares(1) Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • September 25th, 2017 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
Acceleron Pharma Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,405,406 shares of common stock, $0.001 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 810,810 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used he
Loxo Oncology, Inc. 3,150,000 Shares(1) Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • June 15th, 2017 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Loxo Oncology, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwrit
Loxo Oncology, Inc. 3,870,000 Shares(1) Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 5th, 2017 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Loxo Oncology, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no
Catabasis Pharmaceuticals, Inc. 2,500,000 Shares Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • September 23rd, 2016 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • New York
Catabasis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to Cowen and Company, LLC (the “Underwriter”), 2,500,000 shares of common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriter an option to purchase up to 375,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 20 hereof. Any reference herein to the Registration Statement, the Base Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration
TESARO, Inc. 4,650,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • July 7th, 2016 • TESARO, Inc. • Pharmaceutical preparations • New York
TESARO, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of the common stock, $0.0001 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall
Eclipse Resources Corporation 37,500,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • July 5th, 2016 • Eclipse Resources Corp • Crude petroleum & natural gas • New York
Eclipse Resources Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 37,500,000 shares (the “Firm Securities”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”). The Company also proposes to grant to the Underwriters an option to purchase up to 5,625,000 additional shares of Common Stock on the terms set forth in Section 2 (the “Option Securities”; the Option Securities, together with the Firm Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term “Representatives” as used herein shall mean you, as Underwriters. The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Certain terms used herein are defined in Section 21 hereof.
Loxo Oncology, Inc. 1,675,000 Shares(1) Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • May 12th, 2016 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Loxo Oncology, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwrit
Merus B.V. [ ] Common Shares1 (nominal value €0.09 per share) Underwriting AgreementUnderwriting Agreement • May 9th, 2016 • Merus B.V. • Pharmaceutical preparations • New York
Merus B.V., a limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] common shares, nominal value €0.09 per share (the “Common Shares”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ ] additional Common Shares to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the cont
Proteostasis Therapeutics, Inc. [•] Shares Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • February 10th, 2016 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • New York
Proteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•]1 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural
Ardelyx, Inc. 7,500,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 13th, 2016 • Ardelyx, Inc. • Pharmaceutical preparations • New York
Ardelyx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters sh
Loxo Oncology, Inc. 2,500,000 Shares(1) Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • November 12th, 2015 • Loxo Oncology, Inc. • Pharmaceutical preparations • New York
Loxo Oncology, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto to cover over allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the te
TESARO, Inc. 3,400,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • March 9th, 2015 • TESARO, Inc. • Pharmaceutical preparations • New York
TESARO, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of its common stock, $0.0001 par value (“Common Stock”) set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or
TESARO, Inc. 3,200,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 4th, 2014 • TESARO, Inc. • Pharmaceutical preparations • New York
TESARO, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as a representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Representatives and Underwriters s
Epizyme, Inc. Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 3rd, 2014 • Epizyme, Inc. • Pharmaceutical preparations • New York
Epizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Company Shares”), and the persons named in Schedule II hereto (the “Selling Stockholders”) propose to sell to the several Underwriters the number of shares of Common Stock set forth in Schedule II hereto (the “Selling Stockholder Shares”) (such Company Shares and Selling Stockholder Shares collectively being hereinafter called the “Underwritten Securities”). The Company and the Selling Stockholders named in Schedule II hereto also propose to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I and Schedule II, respectively, if any (the
Acceleron Pharma Inc. [ ] Shares (1) Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • September 6th, 2013 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
Citigroup Global Markets Inc. Leerink Swann LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
Onconova Therapeutics, Inc. Shares (1) Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • July 18th, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
Leerink Swann LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
Epizyme, Inc. Shares 1 Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • May 13th, 2013 • Epizyme, Inc. • Pharmaceutical preparations • New York
Epizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. C
TESARO, Inc. [ ] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • June 27th, 2012 • TESARO, Inc. • Pharmaceutical preparations • New York
TESARO, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ ] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain
Cinco Resources, Inc. Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • April 3rd, 2012 • Cinco Resources, Inc. • Crude petroleum & natural gas • New York
Citigroup Global Markets Inc. Wells Fargo Securities, LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
Class A Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • June 20th, 2011 • Zillow Inc • Services-business services, nec • New York
Zillow, Inc., a corporation organized under the laws of Washington (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, shares of Class A common stock, $0.0001 par value per share (“Class A Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Class A Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriters, and the terms Representative and Underwriters shall mean either the singular or plural as the c
Tranzyme, Inc. [ ]Shares Common Stock ($0.00001 par value) Underwriting AgreementUnderwriting Agreement • March 8th, 2011 • Tranzyme Inc • Pharmaceutical preparations • New York
Citigroup Global Markets Inc. BMO Capital Markets Corp. Canaccord Genuity Inc. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters,
FORM OF UNDERWRITING AGREEMENT] Harrah’s Entertainment, Inc. 31,250,000 Shares1 Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • November 16th, 2010 • Harrahs Entertainment Inc • Services-miscellaneous amusement & recreation • New York
Harrah’s Entertainment, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 31,250,000 shares of common stock, $0.01 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 4,687,500 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.
TOWER AUTOMOTIVE, LLC [ ] Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • October 4th, 2010 • Tower Automotive, LLC • Motor vehicle parts & accessories • New York
Tower Automotive, LLC, a limited liability company organized under the laws of the State of Delaware that prior to the delivery of and payment for the Underwritten Securities (as defined below) will convert (such conversion, the “Corporate Conversion”) pursuant to Section 265 of the Delaware General Corporation Law into Tower International, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] shares of common stock, $0.01 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes, subject to the terms and conditions stated herein, to grant to the Underwriters an option to purchase, at any time in whole, or from time to time in part, on o
